Analysts Set Oculis Holding AG (NASDAQ:OCS) Target Price at $25.00

Posted by on Aug 6th, 2023

Shares of Oculis Holding AG (NASDAQ:OCS – Get Free Report) have received a consensus recommendation of “Buy” from the seven ratings firms that are covering the firm, MarketBeat reports. Seven research analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $25.00.

Several research firms have recently commented on OCS. Robert W. Baird began coverage on shares of Oculis in a research report on Wednesday, June 7th. They issued an “outperform” rating for the company. HC Wainwright reaffirmed a “buy” rating and issued a $28.00 target price on shares of Oculis in a research report on Thursday. Bank of America initiated coverage on shares of Oculis in a research report on Wednesday, June 14th. They issued a “buy” rating and a $22.00 target price for the company. Pareto Securities initiated coverage on shares of Oculis in a research report on Wednesday, May 10th. They set a “buy” rating and a $23.00 price target for the company. Finally, Wedbush initiated coverage on shares of Oculis in a research report on Friday, April 28th. They set an “outperform” rating and a $27.00 price target for the company.

Oculis Price Performance

NASDAQ:OCS opened at $12.50 on Thursday. The stock has a 50-day moving average of $12.12. Oculis has a 12 month low of $6.26 and a 12 month high of $13.95.

Institutional Trading of Oculis

Institutional investors and hedge funds have recently bought and sold shares of the company. Barclays PLC bought a new stake in Oculis during the 2nd quarter valued at about $44,000. HRT Financial LP bought a new stake in Oculis during the 1st quarter valued at about $178,000. Compagnie Lombard Odier SCmA bought a new stake in Oculis during the 1st quarter valued at about $472,000. Finally, Nan Fung Group Holdings Ltd bought a new stake in Oculis during the 1st quarter valued at about $4,838,000. 39.02% of the stock is currently owned by institutional investors.

About Oculis

(Get Free Report

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Recommended Stories

Analyst Recommendations for Oculis (NASDAQ:OCS)

Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.